Congress of the United States Washington, DC 20515

June 27, 2019

Honorable Alex M. Azar II Secretary U.S. Department of Health & Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201

Dear Secretary Azar:

We are writing to encourage you to finalize your proposal to modernize the Medicare Part D program to ensure beneficiaries receive pharmaceutical manufacturer price concessions when they fill their prescriptions at the point-of-sale at the pharmacy counter. This reform proposed by the Administration will significantly lower patients' out-of-pocket expenses and promote a more competitive marketplace for prescription drugs.

Many patients are struggling with their out-of-pocket expenses which have escalated, in part, because Part D plans do not use the rebates and discounts they receive from manufacturers to lower beneficiary costs at the point-of-sale. As such, patients are paying cost-sharing based on artificially inflated list prices when they fill their prescriptions and do not feel the direct impact of the substantial price concessions provided by manufacturers to their Part D Medicare plans.

Providing price concessions through retrospective rebates also has the adverse effect of requiring those patients with the highest drug costs to cross-subsidize everyone else, turning the concept of insurance on its head. High out-of-pocket costs undermine patient adherence and expedite beneficiaries through the Part D benefit structure, which has substantially increased the program's reinsurance expenses for costs in the catastrophic phase of the benefit. Reinsurance is the fastest growing component of the Part D program – growing from 8 percent of program expenses in 2007 to 40 percent in 2018. This reform will counter those concerning trends.

While CBO projected this rule could significantly increase Medicare spending over the next 10 years, that analysis is predicated on an unrealistic, static response by Part D plan sponsors. CBO has misjudged Part D spending trends significantly in the past, notably overestimating the cost of the benefit by about 45 percent when it was first enacted. An analysis of the rule by the actuarial firm, Milliman, on the other hand, examined likely behavioral changes including stronger incentives for plans to favor lower cost drugs, more significant discounts, a decrease in brand-name cost growth and other factors, and found federal savings of up to \$97 billion.

We look forward to working with you to lower our seniors' drug costs, particularly by tackling distortions that have emerged in the market, which are preventing negotiated price concessions from reaching the patient. This reform will provide greater transparency, improve adherence, and still preserve every market tool Medicare drug plans need to negotiate aggressively with pharmaceutical manufacturers.

ⁱ Health and Human Services, Trump Administration Proposal to Lower Drug Costs by Targeting Backdoor Rebates and Encouraging Direct Discounts to Patients, (https://www.hhs.gov/about/news/2019/01/31/trump-administration-

proposes-to-lower-drug-costs-by-targeting-backdoor-rebates-and-encouraging-direct-discounts-to-patients.html), January 31, 2019.

"2019 Medicare Trustees Report Table IV.B10, available at (https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/Downloads/TR2019.pdf), March 2019.

Congressional Budget Office, "Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBO's Budget Projections—Supplemental Material for Updated Budget Projections: 2019 to 2029", (https://www.cbo.gov/system/files/2019-05/55151-SupplementalMaterial.pdf), May 2019.

^{iv} J. Klaisner, K. Holcomb and T. Filipek, "A primer on prescription drug rebates: Insights into why rebates are a target for reducing prices", (http://www.milliman.com/insight/2018/A-primer-on-prescription-drug-rebates-Insights-into-why-rebates-are-a-target-for-reducing-prices/) Milliman, Jan. 31, 2019

^v Tara O'Neill Hayes, "The Drug Rebate Rule: What's the Budget Impact?",

(https://www.americanactionforum.org/insight/the-drug-rebate-rule-whats-the-budget-impact/), American Action Forum, May 21, 2019.

Sincerely,

Mark R. Meadows Member of Congress Matt Gaetz

Member of Congress

David P. Roe, M.D.

Member of Congress

Jody Hice

Member of Congress

Roger Marshall, M.D.

Member of Congress

Ken Buck

Member of Congress

Ted Budd

Member of Congress

Denver Riggleman

Member of Congress



1	P.Off	
19		

Sean Duffy Member of Congress

Paul A. Gosar, D.D.S. Member of Congress

Larry Bucshon, M.D.
Member of Congress

Ralph Norman Member of Congress

Tom Graves
Member of Congress

Guy Reschenthaler Member of Congress French Hill Member of Congress

Vicky Hartzler
Member of Congress

Jim Banks Member of Congress

Ben Cline Member of Congress Austin Scott Member of Congress Doug Collins
Member of Congress

Brian Babin, D.S. Member of Congress

H. Morgan Criffith Member of Congress

A. Drew Ferguson, IV DMD Member of Congress

Greg Pence
Member of Congress

. / //

Doug LaMalfa Member of Congress

Tim Burchett
Member of Congress

Jeff Fortenberry Member of Congress John Joyce, M.D. Member of Congress

Francis Rooney
Member of Congress

aime Herrera Beutler Member of Congress

Doug Lamborn
Member of Congress

W Diegory Steube Member of Congress

F James Sensenbrenner, Jr. Member of Congress

Lance Gooden Member of Congress Bill Huizenga Member of Congress

Mike Johnson Member of Congress Kelly Armstrong
Member of Congress

Rick W. Allen Member of Congress

Greg Gianforte
Member of Congress

Michael Guest Member of Congress Glenn Grothman Member of Congress

Anthony Gonzalez

Member of Congress

Alex X. Mooney Member of Congress John Moolenaar Member of Congress

Mike Gallagher Member of Congress

Van Taylor Member of Congress

Bruce Westerman Member of Congress

Bennie G. Thompson Member of Congress

Scott DesJarlais, M.D.
Member of Congress

Earl I Budly Corton

Earl L. "Buddy" Carter Member of Congress

Don Bacon
Member of Congress

Patrick McHenry
Member of Congress

Steve King Member of Congress

Ralph Abraham, M.D. Member of Congress

Mark Walker Member of Congress Kevia Herri Member of Congress

Daniel Webster
Member of Congress

Clay Higgins
Member of Congress

Bradley Byrne Member of Congress

Barry Londermilk Momber of Congress

John Katko Member of Congress

Jack Bergman Member of Congress Steve Chabot Member of Congress

Robert J. Wittman Member of Congress

James Comer Member of Congress

Louie Gohmert Member of Congress Congressman Mike D Rogers Member of Congress Ross Spano

Member of Congress

Jeff Duncan Member of Congress 101

Member of Congress

Duncan Hunter Member of Congress

Virginia Foxx Member of Congress W. The

John Rose Member of Congress

Dusty Johnson Member of Congress William R. Timmons, IV

c. Q. miller

Member of Congress

Roger Williams Member of Congress

Nea P. Dunn, M.D. Member of Congress

John H. Rutherford Member of Congress

Carol D. Miller Member of Congress Trent Kelly
Member of Congress

Andy Harris, M.D. Member of Congress

Susani Books

Susan W. Brooks Member of Congress

Suz Vilson

Joe Wilson

Joe Wilson
Member of Congress

David Rouzer

David Rouzer
Member of Congress

Lee Zeldin Member of Congress

John Shimkus Member of Congress Jim Hagedorn
Member of Congress

Ron Wright Member of Congress

Lif Cleney

Member of Congress

Cathy McMorris Rogers Member of Congress

Russ Fulcher Member of Congress

Glenn "GT" Thompson Member of Congress Member of Congress Michael Waltz Member of Congress Member of Congress K. Michael Conaway Member of Congress Member of Congress John Carter Steve Watkins Member of Congress Member of Congress Ken Zalvert Steve Womack Member of Congress Member of Congress

Member of Congress

Scott Perry

Member of Congress

John Ratcliffe Member of Congress Jodey C. Arrington Member of Congress

Lloyd Smucker Member of Congress